The target of renal anemia correction with erythropoietin stimulating agents (ESAs) has been traditionally set at a hemoglobin (Hb) level of 11 – 12 g/dL. However, a trend has arisen of progressively increasing the Hb level to beyond 12 g/dL. Recent randomized control trials (RCTs) on correction of renal anemia in chronic kidney disease patients found that normalization of anemia to above 13 g/dL was associated with negative outcome parameters, echoing a previous RCT that showed increased death and myocardial infarction risk after normalization of hemoglobin level in hemodialysis patients. The latest consensus is to limit Hb to a level not exceeding 13 g/dL during renal anemia correction with ESAs.
Currently, there are three ESAs available commercially. The choice of ESA should consider safety of subcutaneous administration, cost-effectiveness, and dosing frequency, all of which may affect compliance with ESA administration. Early identification of, and an early search for the causes of hyporesponsiveness to, ESAs is needed to avoid unnecessary escalation in the dose of ESAs. These approaches will help to improve the cost-effectiveness of ESA therapy and permit early detection of hidden problems. The current definitions of hyporesponsiveness are far too stringent and should be reviewed.
CollinsAJLiSSt. PeterWEbbenJRobertsRMaJZ. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol2001; 12:2465–73.
2.
LiSCollinsAJ. Associations of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int2004; 65:626–33.
3.
LiSFoleyRCollinsAJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int2004; 65:1864–9.
4.
Kidney Disease Outcomes Quality Initiative (K/DOQI), National Kidney Foundation.Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Hb range. Am J Kidney Dis2006; 47(Suppl 3):S33–53.
5.
LocatelliFAljamaPBárányPCanaudBCarreraFEckardtKU. on behalf of the European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Targets for anemia treatment. Nephrol Dial Transplant2004; 19(Suppl 2):ii6–15.
6.
United States Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases. USRDS 2007 annual data report. Atlas of end-stage renal disease in the United States. Chapter 5. Bethesda: United States Renal Data System; 2007. [Available online at: www.usrds.org/2007/view/05_clinical_care.asp#;%20return%20false; cited 20 November 2007]
7.
RegidorDLKoppleJDKovesdyC PKilpatrickRDMcAllisterCJAronovitzJ. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol2006; 17:1181–91.
8.
DrüekeTBLocatelliFClyneNEckardtKUMacdougallICTsakirisD. on behalf of the CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med2006; 355:2071–84.
9.
SinghAKSzczechLTangKLBarnhartHSappSWolfsonM. on behalf of the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med2006; 355:2085–98.
10.
BesarabABoltonWKBrowneJKEgrieJCNissensonAROkamotoDM. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med1998; 339:584–90.
11.
FoleyRNParfreyPSMorganJBarréPECampbellPCartierP. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int2000; 58:1325–35.
12.
LevinADjurdjevOThompsonCBarrettBEthierJCarlisleE. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis2005; 46:799–811.
13.
ParfreyPSFoleyRNWittreichBHSullivanDJZagariMJFreiD.Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol2005; 16:2180–9.
14.
United States, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Office of Oncology Drug Products. Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp) [Web page]. Rockville, MD: CDER; 2007. [Available online at: www.fda.gov/cder/Offices/OODP/whatsnew/ESA.htm; cited 7 November 2007]
15.
Kidney Disease Outcomes Quality Initiative (K/DOQI).KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis2007; 50:471–530.
16.
FishbaneSBernsJS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int2005; 68:1337–43.
17.
United States, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).Information for healthcare professionals: Erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)] [FDA alert]. Rockville, MD: CDER; 2007. [Available online at: www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm; cited 20 November 2007]
18.
WishJB. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int Suppl2006; 106:S21–5.
19.
SnyderJJFoleyRNGilbertsonDTVoneshEFCollinsAJ. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol2004; 15:174–9.
20.
KaufmanJSRedaDJFyeCLGoldfarbDSHendersonWGKleinmanJG. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med1998; 339:578–83.
21.
BovenKStrykerSKnightJThomasAvan RegenmortelMKemenyDM. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int2005; 67:2346–53.
22.
SułowiczWBentkowskiWStompórTGrossJBiłykARudzkiZ.Pure red cell aplasia due to treatment with epoietin beta: first case report of PRCA from Poland. Przegl Lek2006; 63:810–14.
23.
ManentiLVaglioA.Pure red cell aplasia followed by disseminated intravascular coagulation in a hemodialysis patient receiving erythropoietin-beta. Nephrol Dial Transplant2007; 22:1465–7.
24.
HowmanRKulkarniH.Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant2007; 22:1462–4.
25.
WaznyLDStojimirovicBBHeidenheimPBlakePG. Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis2002; 40:623–8.
26.
TheodoridisMPassadakisPKrikiPPanagoutsosSYannatosEKantartziK. Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients. Perit Dial Int2005; 25:564–9.
27.
LocatelliFOlivaresJWalkerRWilkieMJenkinsBDeweyCon behalf of the European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int2001; 60:741–7.
28.
Kalantar-ZadehKRegidorDLMcAllisterCJMichaelBWarnockDG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol2005; 16:3070–80.
LocatelliFAljamaPBárányPCanaudBCarreraFEckardtKU. on behalf of the European Best Practice Guidelines Working Group. Revised European best practice guide-lines for the management of anaemia in patients with chronic renal failure. Failure to respond to treatment. Nephrol Dial Transplant2004; 19(Suppl 2):ii32–6.
31.
Kidney Disease Outcomes Quality Initiative (K/DOQI), National Kidney Foundation.Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Evaluating and correcting persistent failure to reach or maintain intended Hb. Am J Kidney Dis2006; 47(Suppl 3):S81–5.
